Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...

CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading ...

Semaglutide 2.4 mg improves insulin sensitivity and glycemic outcomes in adolescents with obesity, according to a secondary analysis of STEP TEENS.

A new Fracture Risk Assessment Tool that includes bone microarchitecture measures outperformed the current tool that uses ...